UCSF Adult Antibiogram

These reports are aggregated from clinical isolates submitted to the UCSF clinical microbiology laboratory from patients at the UCSF Parnassus and Mission Bay campuses and are meant to guide clinicians in selecting empiric therapy. Patient characteristics must be incorporated in determining risks and therapy should be modified based on susceptibility testing results when available. Breakpoints for susceptibility are via CLSI guidelines.

Methodology Notes

Adult Antibiogram 2019 (PDF)

16 Organisms

Citrobacter freundii

Total Isolates CTRX ERTA CTAZ CFPM TOB CIP P/T MER
44 63 98 61 93 84 86 87 95
Year: 2019 | Location: Inpatient, all areas

Notes:

% Strains Susceptible, tested from all sites except as indicated

N/A-testing NOT APPLICABLE to organism. CTRX-ceftriaxone, CFPM-cefepime, CIP-ciprofloxacin,  MER –meropenem, P/T-piperacillin-tazobactam, TOB-tobramycin


E. coli

Total Isolates CTRX ERTA CTAZ CFPM TOB CIP P/T MER
555 69 99 79 78  (91)* 82 61 94 99
Year: 2019 | Location: Inpatient, all areas

Notes:

% Strains Susceptible, tested from all sites except as indicated

N/A-testing NOT APPLICABLE to organism. CTRX-ceftriaxone, CFPM-cefepime ( )* including susceptible dose-dependent isolates, CIP-ciprofloxacin,  MER –meropenem, P/T-piperacillin-tazobactam, TOB-tobramycin


Enterobacter cloacae

Total Isolates CTRX ERTA CTAZ CFPM TOB CIP P/T MER
123 66 91 66 94 (98)* 94 91 72 99
Year: 2019 | Location: Inpatient, all areas

Notes:

% Strains Susceptible, tested from all sites except as indicated

N/A-testing NOT APPLICABLE to organism. CTRX-ceftriaxone, CFPM-cefepime *includes susceptible dose-dependent isolates, CIP-ciprofloxacin,  MER –meropenem, P/T-piperacillin-tazobactam, TOB-tobramycin


Enterococcus faecalis (bloodstream isolates)

Total Isolates AMP NAF CLIN DOX T/S VANC DAP LZD
30 100 N/A N/A 23 N/A 97 100 100
Year: 2019 | Location: Inpatient, all areas

Notes:

% Strains Susceptible, tested from all sites except as indicated

N/A-testing NOT APPLICABLE to organism. PCN-penicillin, NAF-nafcillin, CLIN-clindamycin,  DOX –doxycycline, T/S-trimethoprim/sulfamethoxazole, VANC-vancomycin, DAP-daptomycin, LZD-linezolid


Enterococcus faecium (bloodstream isolates)

Total Isolates AMP NAF CLIN DOX T/S VANC DAP LZD
23 13 N/A N/A 30 N/A 39 100* 100
Year: 2019 | Location: Inpatient, all areas

Notes:

% Strains Susceptible, tested from all sites except as indicated

N/A-testing NOT APPLICABLE to organism. AMP-ampicillin, NAF-nafcillin, CLIN-clindamycin,  DOX –doxycycline, T/S-trimethoprim/sulfamethoxazole, VANC-vancomycin, DAP-daptomycin *isolates are susceptible dose-dependent, LZD-linezolid


Klebsiella aerogenes

Total Isolates CTRX ERTA CTAZ CFPM TOB CIP P/T MER
44 77 95 79 100 100 88 81 97
Year: 2019 | Location: Inpatient, all areas

Notes:

% Strains Susceptible, tested from all sites except as indicated

N/A-testing NOT APPLICABLE to organism. CTRX-ceftriaxone, CFPM-cefepime, CIP-ciprofloxacin,  MER –meropenem, P/T-piperacillin-tazobactam, TOB-tobramycin


Klebsiella oxytoca

Total Isolates CTRX ERTA CTAZ CFPM TOB CIP P/T MER
45 84 100 84 91 (98)* 84 84 86 100
Year: 2019 | Location: Inpatient, all areas

Notes:

% Strains Susceptible, tested from all sites except as indicated

N/A-testing NOT APPLICABLE to organism. CTRX-ceftriaxone, CFPM-cefepime *(including susceptible dose-dependent isolates), CIP-ciprofloxacin,  MER –meropenem, P/T-piperacillin-tazobactam, TOB-tobramycin


Klebsiella pneumoniae

Total Isolates CTRX ERTA CTAZ CFPM TOB CIP P/T MER
206 77 94 80 80 (90)* 83 82 88 97
Year: 2019 | Location: Inpatient, all areas

Notes:

% Strains Susceptible, tested from all sites except as indicated

N/A-testing NOT APPLICABLE to organism. CTRX-ceftriaxone, CFPM-cefepime *including susceptible dose-dependent isolates, CIP-ciprofloxacin,  MER –meropenem, P/T-piperacillin-tazobactam, TOB-tobramycin


Proteus mirabilis

Total Isolates CTRX ERTA CTAZ CFPM TOB CIP P/T MER
122 94 100 95 95 (98)* 88 72 99 100
Year: 2019 | Location: Inpatient, all areas

Notes:

% Strains Susceptible, tested from all sites except as indicated

N/A-testing NOT APPLICABLE to organism. CTRX-ceftriaxone, CFPM-cefepime *including susceptible dose-dependent isolates, CIP-ciprofloxacin,  MER –meropenem, P/T-piperacillin-tazobactam, TOB-tobramycin


Pseudomonas aeruginosa

Total Isolates CTRX ERTA CTAZ CFPM TOB CIP P/T MER
238 N/A N/a 89 91 97 84 85 89
Year: 2019 | Location: Inpatient, all areas

Notes:

% Strains Susceptible, tested from all sites except as indicated

N/A-testing NOT APPLICABLE to organism. CTRX-ceftriaxone, CFPM-cefepime, CIP-ciprofloxacin,  MER –meropenem, P/T-piperacillin-tazobactam, TOB-tobramycin


Serratia marcescens

Total Isolates CTRX ERTA CTAZ CFPM TOB CIP P/T MER
51 96 100 100 100 100 98 100 100
Year: 2019 | Location: Inpatient, all areas

Notes:

% Strains Susceptible, tested from all sites except as indicated

N/A-testing NOT APPLICABLE to organism. CTRX-ceftriaxone, CFPM-cefepime, CIP-ciprofloxacin,  MER –meropenem, P/T-piperacillin-tazobactam, TOB-tobramycin


Staphylococcus aureus

Total Isolates PCN NAF CLIN DOX T/S VANC DAP LZD
562 N/A 73 73 91 95 100 100 100
Year: 2019 | Location: Inpatient, all areas

Notes:

% Strains Susceptible, tested from all sites except as indicated

N/A-testing NOT APPLICABLE to organism. PCN-penicillin, NAF-nafcillin, CLIN-clindamycin,  DOX –doxycycline, T/S-trimethoprim/sulfamethoxazole, VANC-vancomycin, DAP-daptomycin, LZD-linezolid


Staphylococcus aureus, MRSA

Total Isolates PCN NAF CLIN DOX T/S VANC DAP LZD
148 N/A N/A 56 88 90 100 100 100
Year: 2019 | Location: Inpatient, all areas

Notes:

% Strains Susceptible, tested from all sites except as indicated

N/A-testing NOT APPLICABLE to organism. PCN-penicillin, NAF-nafcillin, CLIN-clindamycin,  DOX –doxycycline, T/S-trimethoprim/sulfamethoxazole, VANC-vancomycin, DAP-daptomycin, LZD-linezolid


Staphylococcus aureus, MSSA

Total Isolates PCN NAF CLIN DOX T/S VANC DAP LZD
422 N/A 100 78 93 97 100 100 100
Year: 2019 | Location: Inpatient, all areas

Notes:

% Strains Susceptible, tested from all sites except as indicated

N/A-testing NOT APPLICABLE to organism. PCN-penicillin, NAF-nafcillin, CLIN-clindamycin,  DOX –doxycycline, T/S-trimethoprim/sulfamethoxazole, VANC-vancomycin, DAP-daptomycin, LZD-linezolid


Staphylococcus epidermidis

Total Isolates PCN NAF CLIN DOX T/S VANC DAP LZD
248 N/A 38 60 89 51 100 100 100
Year: 2019 | Location: Inpatient, all areas

Notes:

% Strains Susceptible, tested from all sites except as indicated

N/A-testing NOT APPLICABLE to organism. PCN-penicillin, NAF-nafcillin, CLIN-clindamycin,  DOX –doxycycline, T/S-trimethoprim/sulfamethoxazole, VANC-vancomycin, DAP-daptomycin, LZD-linezolid


Streptococcus pneumoniae

Total Isolates PCN CTRX CLIN DOX T/S VANC DAP LZD
562 100 (72)* 100 (83)* 94 94 94 100 N/T N/T
Year: 2019 | Location: Inpatient, all areas

Notes:

% Strains Susceptible, tested from all sites except as indicated

N/A-testing NOT APPLICABLE to organism. PCN-penicillin *susceptibility based on meningitis breakpoint, CTRX-ceftriaxone *susceptibility based on meningitis breakpoint, CLIN-clindamycin,  DOX –doxycycline, T/S-trimethoprim/sulfamethoxazole, VANC-vancomycin, DAP-daptomycin, LZD-linezolid, N/T-not tested